The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
We are building an AI-native operating system for pharma sales and distribution
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
Subscribe To Our Newsletter & Stay Updated
